People

The People

Grade: C+. Founder-led, founder-aligned, and founder-dependent — Ron Loucks runs the company he started in 2003, still owns 10.5% of the common stock plus a disproportionate slice of the preferred, and draws a sensible C$313K. Skin in the game is excellent. The concerns are structural: a five-person board with two of five seats occupied by 20%+ beneficial holders, no visible committee architecture, an opaque preferred-share class controlled by insiders, a director the shareholders voted against in 2024 who was quietly re-appointed five months later, and a succession plan that consists of one 22-year-incumbent CEO and whoever is next to him in the room.

1. The People Running This Company

NexgenRx is effectively a founder-operated company with a thin but domain-specialized executive bench. The management team is built around one person — Ron Loucks — with a long-tenured CFO, a long-tenured operations lead, and a mostly-new technology and implementation layer hired between 2021 and 2025.

Binder Error: Set operations can only apply to expressions with the same number of result columns

What to trust. The CEO has actually built and sold a Canadian benefits-adjudication business before (Assure Health → BCE Emergis, 1999) — this is not a first-time operator. The CFO has been in the seat for a decade, which matters for a TSXV-listed company where continuity of finance function is the first line of defense against reporting error. The VP Operations is a lifer in the sub-industry.

What to doubt. There is no named President, no named COO, and no named CTO — the VP titles collapse those functions into a thin ring around the founder-CEO. If Ron Loucks is unavailable tomorrow, succession is not obvious. Mark Payne has run the technology platform for four years, and Kelly Ehler has run finance for nine, but neither has CEO-level reps. The 2025 hire of Richard Stevens as VP Administration suggests management is finally thickening the bench, but it's a recent development and nothing indicates a named successor has been identified.

2. What They Get Paid

Read. At roughly C$313K total, Ron Loucks is paid less than a mid-level software engineer at a large Canadian bank — and roughly 1.2% of NexgenRx's market cap per year. The mix is 75% cash salary / 25% equity-linked, which is inverted from a typical tech-company pay structure but defensible at this scale: the CEO already owns 10.5% of the common shares outright (worth ~C$2.2M), so option grants are a rounding error on his total wealth tied to the company. Pay is sensible for a C$27M micro-cap with C$15M revenue, and it's notably restrained for a 22-year founder-operator in Canada's public markets.

3. Are They Aligned?

This is the strongest section of the governance case. The ownership stack is unusually concentrated in active directors and officers for a TSXV company, and two of the top five holders sit on the board.

Ownership

Three observations matter.

One: insiders and the single largest non-officer holder together control roughly 37% of the common shares and 32% of the Series 1 preferred. This is a controlled-company profile in practice, even if not in name — a hostile bidder cannot win here without Loucks and Crossett.

Two: the Series 1 preferred shares (6.6M in 2022, unchanged since in disclosed data) are not traded on any stock exchange and are disproportionately held by insiders (Loucks 13.8%, Corcoran 6.9%, Crossett 11.4% — three insiders hold 32% of the preferred). This is a private-company capital structure layered on top of a public one, and the economics (dividend priority, conversion, voting) are disclosed in the MIC we cannot access. Treat this as an unassessed risk, not a resolved one.

Three: Paul E. Crossett, the 20.07% common holder, is classified as an insider by MarketScreener but holds no disclosed board seat and no management role. A 20% owner with no board representation is either passive long-term capital (benign) or a control block just outside the governance wall (concerning). Our data cannot distinguish.

Dilution and capital return

Binder Error: Set operations can only apply to expressions with the same number of result columns

Read. Share count has crept up by roughly 1% over four years — minimal dilution, unusual for a growth-stage micro-cap, and directly aligned with a founder who already owns 10%+ of the float. Capital return is instead the policy: quarterly dividends began in 2022, scaled to roughly 2c/share annualized in 2025, and consumed C$1.30M in the most recent year against C$1.29M net income. The payout ratio hovers around 100% — the company is distributing essentially all of its reported earnings as dividends, which is a choice only a board with no acquisition ambitions and no growth-reinvestment hunger makes.

Skin-in-the-game score

4. Board Quality

The board is small (5 members), long-tenured at the top, and lacks the committee architecture typically disclosed by a Canadian public company even at the TSXV level — or rather, our inability to retrieve the MIC leaves committee composition and independence determination an unverifiable claim. What we can observe from press releases and third-party aggregators is below.

The 2024 Majority Voting Policy event

This single sequence is the most concrete governance data point we have, and it colors interpretation of everything else. It is a legalistic fulfillment of a shareholder democracy mechanism, not a substantive one. Whether it was justified (e.g., the withhold campaign was ill-informed, the board judged Burns indispensable, the re-appointment terms differed) is knowable only from the MIC — which we cannot retrieve.

Missing expertise

• No named cybersecurity director. NexgenRx processes drug, dental, and health claims — inherently PHI-laden data — and the MD&A explicitly calls out cyber security as a risk factor. No director bio discloses a security or IT-risk specialization.
• No named audit-chair CFO / finance-industry director. The CFO's CPA credentials cover the finance function; an outside financial expert on the audit committee is a TSX/TSXV requirement but the audit committee composition is not disclosed in our accessible sources.
• No named independent compensation chair. With 75/25 cash/equity pay mix and a 100% payout ratio, a compensation committee's judgment matters. We cannot observe who exercises it.
• No gender diversity until Oct 2024. Linda Brennan appears to be the first woman on the board in the disclosed roster. Canadian TSXV companies are not required to disclose diversity targets, but the single appointment after 21 years is a fact worth noting.

5. The Verdict

Binder Error: Set operations can only apply to expressions with the same number of result columns

Strongest positives

1. Founder still holds ~10% of common and ~14% of preferred with annual cash comp of C$235K — compensation is a rounding error on his equity stake. He is incentivized as a shareholder, not as an employee.
2. Minimal dilution over four years (+1.1% share count) while returning capital through dividends paid at roughly 100% of earnings. This is the opposite of the "insiders enrich themselves via options grants" pattern that plagues TSXV micro-caps.
3. Long CFO tenure (9 years) and long operations VP tenure (8 years) — operational continuity in the functions that most commonly fail at this scale.
4. CEO has a real prior exit (Assure Health to BCE Emergis). This is not a story-stock founder.

Real concerns

1. No visible succession path. Loucks is 22 years in role; no named President, COO, or deputy. For a company whose value is roughly "recurring revenue from proprietary adjudication software plus founder relationships with pharma PSP clients," a founder succession event is a material risk.
2. Board independence is structurally limited. At most one director (Corcoran) is labeled independent by third-party data; the other four include the CEO plus two 5%+ holders. Two of the five directors joined the board in the same month of 2024.
3. The 2024 Burns re-appointment is a legalistic use of the Majority Voting Policy that undermines confidence that shareholder votes materially constrain the board.
4. Disclosure opacity on preferred shares, committee composition, related-party transactions, and insider trading activity. Some of this is SEDAR+'s fault (access blocked), but a mid-reputation micro-cap would be well-served by mirroring MIC content directly on its IR site. NexgenRx's IR page is a single paragraph and a contact form.
5. Paul E. Crossett's 20% common stake has no visible board representation and no publicly documented relationship to management. A 20% unexplained holder is always worth understanding.

One thing that would upgrade this to B / B+

A named successor with defined transition timing. NexgenRx's business is sticky — recurring C$15M revenue, growing 8–9% per year, now cash-flow positive enough to sustain a 4%-yield dividend. The governance discount on this story today is almost entirely a key-person discount. Either a publicly named President with a path to CEO, or an external hire with an explicit succession timeline, converts this from "good single-person operation" to "durable franchise."

One thing that would downgrade this to C / C-

A discovery via a retrievable MIC that (a) a material related-party transaction flows to the CEO, a director, or Crossett, or (b) the Series 1 preferred structure carries voting or redemption terms that entrench the insider bloc beyond what common-share ownership implies. Either finding recasts the full alignment picture. We cannot rule it out from available data.